



(51) International Patent Classification:

C07D 401/04 (2006.01) *A61P 25/02* (2006.01)
C07D 403/04 (2006.01) *A61P 25/16* (2006.01)
A61K 31/443 (2006.01) *A61P 25/28* (2006.01)

(21) International Application Number:

PCT/US2015/010262

(22) International Filing Date:

6 January 2015 (06.01.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/925,363 9 January 2014 (09.01.2014) US

(71) Applicant: BRISTOL-MYERS SQUIBB COMPANY

[US/US]; Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).

(72) Inventors: **KING, Dalton**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **THOMPSON III, Lorin A.**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **SHI, Jianliang**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **THANGATHIRUPATHY, Srinivasan**; c/o Syngene International Limited, Biocon Park, Plot Nos. 2&3, Bommasandra IV Phase, Jigani Link Road, Karnataka, Bangalore 560099 (IN). **WARRIER, Jayakumar Sankara**; c/o Syngene International Limited, Biocon Park, Plot Nos. 2&3, Bommasandra IV Phase, Jigani Link Road, Karnataka, Bangalore 560099 (IN). **IS-LAM, Imadul**; 3184 Garrity Way, #333, Richmond, California 94806 (US). **MACOR, John E.**; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).


(74) Agents: **EPPERSON, James** et al.; Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH,

[Continued on next page]

(54) Title: SELECTIVE NR2B ANTAGONISTS



(57) Abstract: The disclosure generally relates to compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.



GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*